BobbyQuentinLanierMDFAAAI,FACAAI, PI

PubMed

• 1 citations
  The American College of Allergy, Asthma & Immunology: An 80-year legacy of accomplishments (1942-2022), part 3: Events and achievements (2012-2022).
  Joseph A Bellanti, Bobby Q Lanier, Daniel Ein, Ira Finegold, Chris Foster, Gailen D Marshall Jr, Bryan L Martin, Viviana Maria Temino, Dana V Wallace, Myron J Zitt> ;Annals of Allergy, Asthma & Immunology. 2022 Oct 1
• 7 citations
  Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations
  William W. Busse, Stanley J. Szefler, Tmirah Haselkorn, Ahmar Iqbal, Benjamin Ortiz, Bobby Q. Lanier, Bradley E. Chipps> ;The Journal of Allergy and Clinical Immunology. in Practice. 2021 Mar 1
• 12 citations
  Exploring factors associated with health disparities in asthma and poorly controlled asthma among school-aged children in the U.S.
  Patrick W. Sullivan, Vahram Ghushchyan, Prakash Navaratnam, Howard S. Friedman, Abhishek Kavati, Benjamin Ortiz, Bobby Q. Lanier> ;The Journal of Asthma. 2020 Mar 1
• 15 citations
  Phenotypic and functional alterations of regulatory B cell subsets in adult allergic asthma patients
  Mathew Wiest, Katherine Upchurch, Mahmudul Hasan, Jacob Cardenas, Bobby Lanier, Mark Millard, Jacob Turner, Sangkon Oh, HyeMee Joo> ;Clinical and Experimental Allergy. 2019 Sep 1
• 44 citations
  The national burden of poorly controlled asthma, school absence and parental work loss among school-aged children in the United States.
  Patrick W. Sullivan, Vahram Ghushchyan, Prakash Navaratnam, Howard S. Friedman, Abhishek Kavati, Benjamin Ortiz, Bobby Q. Lanier> ;The Journal of Asthma. 2018 Jun 1
• 8 citations
  Clinical implications of CD4 + T cell subsets in adult atopic asthma patients
  Matthew Wiest, Katherine Upchurch, Wenjie Yin, Jerome Ellis, Yaming Xue, Bobby Lanier, Mark Millard, HyeMee Joo, Sangkon Oh> ;Allergy, Asthma, and Clinical Immunology. 2018 Mar 2
• 1 citations
  Successful long-term, adjunctive use of guaifenesin in a patient with a complex atopic medical history and primary immune deficiency: A case report.
  Bobby Q. Lanier, Judi A. Lapsley Miller> ;Respiratory Medicine Case Reports. 2018 Jan 1
• 36 citations
  National Prevalence of Poor Asthma Control and Associated Outcomes Among School-Aged Children in the United States.
  Patrick W. Sullivan, Vahram Ghushchyan, Prakash Navaratnam, Howard S. Friedman, Abhishek Kavati, Benjamin Ortiz, Bobby Q. Lanier> ;The Journal of Allergy and Clinical Immunology. in Practice. 2017 Aug 1
• 3 citations
  Tissue loss with subcutaneous immunotherapy—Nicolau syndrome
  Millard L. Tierce, Steven M. Schultz, Bobby Q. Lanier> ;The Journal of Allergy and Clinical Immunology. in Practice. 2016 Jan 1
• 38 citations
  Safety and tolerability of a short ragweed sublingual immunotherapy tablet
  Hendrik Nolte, Niran J. Amar, David I. Bernstein, Bobby Q. Lanier, Peter S. Creticos, Gary D. Berman, Amarjot Kaur, Jacques Hébert, Jennifer Maloney> ;Annals of Allergy, Asthma & Immunology. 2014 Jul 1
• 3 citations
  Beclomethasone dipropionate nasal aerosol with an integrated dose counter: functionality and performance.
  Eli O. Meltzer, Phillip E. Korenblat, Bobby Q. Lanier, Leith Kelley, Sudeesh K. Tantry> ;Allergy and Asthma Proceedings. 2013 Nov 1
• 2 citations
  Current standards and future directions in immunotherapy: perspectives on challenges and opportunities for the allergist.
  David I. Bernstein, Michael S. Blaiss, Linda Cox, Ira Finegold, Bobby Q. Lanier, Harold S. Nelson, Dana Wallace> ;Annals of Allergy, Asthma & Immunology. 2011 Nov 1
• 21 citations
  Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis
  Bruce M. Prenner, Bobby Q. Lanier, David I. Bernstein, Tulin Shekar, Ariel Teper> ;The Journal of Allergy and Clinical Immunology. 2010 Jun 1
• Safety and Tolerability of Omalizumab
  J Corren, B Lanier> ;Wiley. 2009 Jun
• 29 citations
  Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 μg in the treatment of seasonal allergic rhinitis
  Michael A. Kaliner, William W. Storms, Stephen A. Tilles, Sheldon L. Spector, Ricardo A. Tan, Craig LaForce, Bobby Q. Lanier, Bradley E. Chipps> ;Allergy and Asthma Proceedings. 2009 May 1
• 7 citations
  Prevalence and Impact of Nighttime Symptoms in Adults and Children With Asthma: A Survey
  Bobby Q. Lanier, Anjuli Nayak> ;Postgraduate Medicine. 2008 Nov 1
• 35 citations
  State of world allergy report 2008: allergy and chronic respiratory diseases.
  Ruby Pawankar, Carlos E Baena-Cagnani, Jean Bousquet, G Walter Canonica, Alvaro A Cruz, Michael A Kaliner, Bobby Q Lanier> ;The World Allergy Organization Journal. 2008 Jun 1
• 14 citations
  State of world allergy report 2008 allergy and chronic respiratory diseases.
  Ruby Pawankar, Carlos E Baena-Cagnani, Jean Bousquet, G Walter Canonica, Alvaro A Cruz, Michael A Kaliner, Bobby Q Lanier> ;The World Allergy Organization Journal. 2008 Jun 1
• Comparison of diphenhydramine and nonsedating antihistamines for the treatment of acute allergic reactions.
  Bobby Q Lanier> ;Allergy and Asthma Proceedings. 2008 Jan 1
• 98 citations
  Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance, and satisfaction
  Bradley F. Marple, John A. Fornadley, Alpen A. Patel, Stanley M. Fineman, Leonard Fromer, John H. Krouse, Bobby Q. Lanier, Peter Penna> ;Otolaryngology--Head and Neck Surgery. 2007 Jun 1
• 29 citations
  Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
  Bobby Q. Lanier, Ira Finegold, Peter A. D'Arienzo, David B. Granet, Arthur B. Epstein, Greg L. Ledgerwood> ;Current Medical Research and Opinion. 2004 Aug 1
• 1388 citations
  Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.
  S.G.O. Johansson, Thomas Bieber, Ronald Dahl, Peter S. Friedmann, Bobby Q. Lanier, Richard F. Lockey, C. Motala, José Antonio Ortega Martell, Thomas A.E. Platts-Mills,...> ;The Journal of Allergy and Clinical Immunology. 2004 May 1
• 5 citations
  Unanswered questions on omalizumab (Xolair) patient selection and follow-up.
  Bobby Q. Lanier, Gailen D. Marshall> ;Annals of Allergy, Asthma & Immunology. 2004 Feb 1
• 134 citations
  Omalizumab is effective in the long-term control of severe allergic asthma.
  Bobby Quentin Lanier, Jonathan Corren, William R. Lumry, Jeen Liu, Angel FowlerTaylor, Niroo Gupta> ;Annals of Allergy, Asthma & Immunology. 2003 Aug 1
• Patient education doesn't work--"edu-tainment" does.
  Bobby Q. Lanier> ;Annals of Allergy, Asthma & Immunology. 2003 Aug 1
• Join now to see all

Journal Articles

• Think twice before Choosing Wisely  
  Lanier B, Tex Med, 1/1/2015
• Safety and tolerability of a short ragweed sublingual immunotherapy tablet  
  Nolte H, Amar N, Bernstein DI, Lanier BQ, Creticos P, Berman G, Kaur A, Hébert J, Maloney J, Ann Allergy Asthma Immunol, 1/1/2014
• Beclomethasone dipropionate nasal aerosol with an integrated dose counter: functionality and performance  
  Meltzer EO, Korenblat PE, Lanier BQ, Kelley L, Tantry SK, Allergy Asthma Proc, 1/1/2013
• Use of intranasal corticosteroids in the management of congestion and sleep disturbance in pediatric patients with allergic rhinitis  
  Lanier BQ, Clinical Pediatrics, 1/1/2008
• Pathophysiology and Progression of Nasal Septal Perforation  
  Lanier BQ, Allergy Asthma Immunology, 1/1/2007
• Baboon Syndrome Induced by Mercury-First Case Report in China  
  Lanier BQ, Contact Dermatitis, 1/1/2007
• Unanswered questions and speculations about the role of anti-immunologlobulin E in atopic and nonatopic disease  
  Lanier, Bob Q, Allergy Asthma Proceedings, 1/1/2006
• Unanswered Questions and Warnings Involving Anti-Immunoglobulin E Therapy Based on 2-Year Observation of Clinical Experience  
  Lanier, Bob Q, Proceedings of Allergy Asthma and Immunology, 1/1/2005
• Will Anti-IgE therapt Compromise Normal Immune Functions?  
  Lanier BQ, Chang TW, Allergy & Clinical Immunology International, 1/1/2004
• Omalizumab in the Treatment of Allergy and Asthma, Drug profile  
  Lanier BQ, Carr W, Therapy, 1/1/2004
• Clinical Effecacy of Olopatadine vs epinsatine ophthalmic solution in the conjunctival allergen challenge Model  
  Lanier BQ, Finegold I, D'Arienzo PA, Current Medical Research, 1/1/2004
• Unanswered questions on Omalzumab (Xolair) patient Selection and Follow-up  
  Lanier, BQ, Marshall GD Jr, Ann Allergy Asthma Immunol, 1/1/2004
• Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of children with acute otitis media with otorrhea through t...  
  Roland PS, Kreisler LS, Reese B, Anon JB, Lanier BQ, et al, Pediatrics, 1/1/2004
• Patient education doesn't work-"edu-tainment" does  
  Lanier BQ, Annals of Allergy, 1/1/2003
• Omalizumab is Effective in the Long-Term Control of Severe Allergic Asthma  
  Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor AR, Gupta N, Annals of Allergy, 1/1/2003
• Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhi...  
  Lanier BQ, Ableson MB, Berger WE, Granet DB, D'Arienzo PA, Spanlger DL, Kagi MK, Clinical Therapeutics, 1/1/2002
• Immunotherapy for asthma  
  Finegold I, Lanier BQ, Berger W, Blaiss M, Am J Respir Crit Care Med, 1/1/2002
• Anti-IgE in the real world  
  Lanier BQ, Annals of Allergy, 1/1/2002
• When the whole is more than the sum of it's parts  
  Lanier BQ, Annals of Allergy, Asthma, and Immunology, 1/1/2001
• Anti-IgE Recombinant Humanized Monoclonal Antibody, for the Treatment of Severe Allergic Asthma  
  Busse W, Coren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, Van As A, Gupta N, Omalizumab, J Allergy Clin Immunol, 1/1/2001
• No Prescription Needed-No Doctor Either  
  Lanier BQ, Annals of Allergy, Asthma & Immunology, 1/1/2001
• New Treatments and the Future Role of Immunotherapy: Anti-IgE  
  Lanier BQ, Annals of Allergy, Asthma & Immunology, 1/1/2001
• Olopatadine Ophthalmic Solution Adjunctive to Loratadine Compared to Loratadine Alone in Patients With Active Seasonal Allergic Conjunctivitis Symptoms  
  Lanier BQ, Gross R D, Marks B, Cockrum PC, Juniper EF, Annals of Allergy, Asthma, and Immunology, 1/1/2001
• Increased Time to First Asthma Exacerbation Seen in Xolair Treated Patients Compared with Placebo  
  Nelson H, Fick R, Fowler-Taylor A, Ashby M, Busse W, Chervinsky P, Lanier BQ, Gupta N, Corren J, Rohane P, Ann. Allergy Asthma Immunol, 1/1/2001
• Long-term Safety and Tolerability of Xolair-A Double Blind, Placebo-Controlled Study  
  Berger W, Nayak A, Fowler-Taylor A, Chervinsky P, Busse W, Lanier BQ, Corren J, Gupta N, Rohane P, Fick R, Ann. Allergy Asthma Immunol, 1/1/2001
• Join now to see all

Books/Book Chapters

• "Allergy and Imunology" 
  Chapter: Anti-IgE pathophysiology and applications. 
  Lanier BQEditors: Lieberman and Anderson.2006
• "Atlas of Allergy" 
  Chapter: Anti-IgE 
  Lanier BQEditors: Blaiss, Liberman.2005

Abstracts/Posters

• Long-term safety and efficacy of QMF149, a once-daily, fixed-dose combination of indacaterol and mometasone furoate, in patients with persistent asthma.
  Bob Lanier, David Pearlman, Thomas Casale, Richard Beasley, Allen Moton, Han-Joo Kim, Bettina Hederer, ATS, 1/1/2012
• "The Effect of Bepotastine Besilate Ophthalmic Solution 1.5% on Prick Skin Test Reactivity measured with Histamine Controls"
  Lanier BQ Jones,D. Marks, B, AAAAI, 1/1/2011
• "Number needed to treat to prevent one exacerbation per year with omalizumab in children with inadequately controlled allergic (IgE-mediated) asthma"
  Lanier BQ, ERS, 1/1/2010
• Is there a role for Anti-IgE I the treatment of asthma in developing countries.
  Lanier BQ, AAPCI, 1/1/2010
• Rhinitis, Ocular disorders and Aerobiology.
  Lanier BQ, Session "A", ACAAI Meeting, 1/1/2009
• Efficacy and Safety of Omalizumab Added to Optimize Asthma Care in Children.
  Lanier BQ, European Respiratory Association, 1/1/2008
• "Safety and Efficacy of Olepatidine .6% Nasal spral in Perienial allergic rhinitis"
  Lanier BQ, AAAAI Annual Meeting 2006, Miami, FL, 1/1/2006
• Anaphylaxis with SIT while being treated with Xolair.
  Lanier BQ, European Academy of Allergology and Clinical Immunology, Munich, 1/1/2005
• "IgE does not consistently rise with anti-IgE therapy"
  Lanier BQ, ACAAI Annual Meeting 2005, Anaheim, CA, 1/1/2005
• "IgE does not protect against anaphylaxis with SIT"
  Lanier BQ, ACAAI Annual Meeting 2005, Anaheim, CA, 1/1/2005
• Safety Of Fexofenadine In Pre-School Children With Allergic Rhinitis.
  Lanier BQ, Hampel F, Kittner B, Varghese ST, American Academy of Pediatrics, 2005 National Conference and Exhibition, Washington, DC, 1/1/2005
• Once-daily treatment with ciclesonide is effective and well tolerated in children with persistent asthma.
  G.Shapiro, G. Bensch R. Lanier, L. Sher M. Lloyd, S. Kundu, J. Williams, D. Banerji, Annual Meeting AAAAI, San Antonio, TX, 1/1/2005
• Omalizumab is well tolerated in adolescent/adult patients(>=12 years) with moderate-to-severe persistent asthma.
  Lanier BQ, Miller D, ATS Meeting, 1/1/2005
• Omalizumab is well tolerated in adolescent/adult patients(>=12 years) with moderate-to-severe persistent asthma.
  Lanier BQ, Casale TB, AAAI Annual Meeting, 1/1/2005
• New Beclomethasone Diporionate Extrafine Aerosol is Effective Pediatric Asthma Therapy.
  Weinstein SF(a), Welch MJ, Lanier BQ, Nayak A, Stampone P, 58th Annual Meeting of the American Academy of Allergy Asthma and Immunology, NY, 1/1/2002
• Omalizumab Significantly Increases Time to First Asthma Exacerbation Compared with Placebo.
  Tillinghast J(a), Lanier BQ, Busse W, Chervinsky P, Ashby M, Fowler-Taylor A, Fick R, Gupta N, XXth Congress of the European Academy of Allenology and Clinical Immunology, Berlin, Germany, 1/9/2001
• Evidence of the Long-term Safety and Tolerability of Omalizumab from a Large Phase III Study.
  Lumry W(a), Berger W, Corren J, Lanier BQ, Busse W, Chervinsky P, Nayak A , Fowler-Taylor A, Fick R, Gupta N, XXth Congress of the European Academy of Allenology and Clinical Immunology, Berlin, Germany, 1/9/2001
• Omalizumab Improves Asthma-specific Quality Of Life (QoL): An Analysis Of Data From 1071 Patients.
  Busse W, Corren J, Lanier BQ, Everhard F, Surrey K, Kirchdorfer L, AAAAI, 1/1/2001
• Multi-media intervention in numerous emergency room admissions.
  Lanier,BQ, American College of Allergy, Asthma, and Clinical Immunology, 1/1/1998
• Triamcinolone Acetonide Aqueous Nasal Spray Does Not Alter Adrenocortical Function in Children With Allergic Rhinitis.
  A. Nayak, M.D., G. Feiss, M.S., J.A. Furst, B.S., B. Simpson, B.S., J.A. Smith, M.D., Easton, P.A., American Academy of Allergy Asthma and Immunology Annual Meeting, New Orleans, LA, 1/1/1996
• The Effect of Asthma Support Groups on Patient Behavior.
  Lanier, BQ, Sanders, N, American College of Allergy, Asthma, and Clinical Immunology, 1/1/1995
• Plasma Cell Antigen on the Surface of Lymphocytes in Immunodeficient Patients.
  Lanier, B.Q., Goldman, A.S., and Harris, N.A., Annual Meeting of the Reticuloendothelial Society, 1/1/1974
• Join now to see all

Lectures

• "Development of Omalizumab" 
  Kuala Lumpur, Malaysia - 1/1/2014
• "Use of Omalizumab in Severe Allergic Asthma" 
  Kuala Lumpur, Malaysia - 1/1/2014
• "Considerations of cost effectiveness of Xolair in Severe Allergic Asthma in developing countries." 
  Kuala Lumpur, Malaysia - 1/1/2014
• "Omalizumab in children" 
  Italy - 1/1/2014
• "Omalzumab in children: cost effectiveness" 
  1/1/2013
• Join now to see all

Other

• Prevalence and Impact of Nighttime Symptoms in Adults and Children with Asthma: A Survey. 
  Lanier, BQ, Nyak, A, Postgraduate Medicine v 120, number 4
  1/1/2008
• Urban Eye Allergy Syndrome: A New Clinical Entity? 
  Lanier BQ, Current Medical Residency Opinion
  1/1/2008
• "Baboon Syndrome Contact Dermatitis" 
  Liping, W, Yin, J, Lanier B
  1/1/2007
• "Allergy-On The Rise and in the News" 
  Lanier BQ, Refractive Eye Care, V10 Number 2
  1/1/2006
• Analysis of the Efficacy of Technical Presentations As a Means of Sharing Data and Modifying Behavior of Professionals. 
  Lanier, BQ, Xolair Source
  1/1/2004
• "Surviving a Hospital Stay" 
  Lanier BQ, Oprah
  1/1/1999
• "Allergies-fact and myth" 
  Lanier BQ (Talent), Schering Cable Television Half Hour
  1/1/1995
• "Allergies-how to survive" 
  Lanier BQ (Talent), Schering Cable Television Half Hour
  1/1/1995
• "Interactive Cases in Asthma" (CD-ROM) 
  Lanier BQ
  1/1/1995
• "Medical Talk Etc..." 
  Lanier BQ (Talent), KCBI Radio (weekly medical talk show)
  1/1/1993
• "Good news about heart attack treatment" (30 minute broadcast documentary) 
  Lanier BQ (Talent, Producer, Writer)
  1/1/1990
• "Apathy" 
  Lanier, B.Q., Medical Portfolio
  1/1/1989
• A Matter of Opinion "A National Disgrace" 
  Lanier, B.Q., Tarrant County Physician
  1/1/1989
• "Doctors and Unions" 
  Lanier, B.Q., Medical Portfolio Volume 8, No. 2
  1/1/1988
• "Homeless" 
  Lanier, B.Q., Cortlandt Group
  1/1/1988
• Malpractice and Lawyers" 
  Lanier, B.Q., Medical Portfolio, Volume 7, No. 1
  1/1/1988
• "Malpractice Prevention" 
  Lanier, B.Q., Medical Portfolio Volume 6, No. 3
  1/1/1987
• "Lawyer Bashing" 
  Lanier, B.Q., Medical Portfolio, Vol. 7, No. 3
  1/1/1987
• "The New Charlatans" 
  Lanier, B.Q., RTNDA Communicator
  1/1/1987
• A Matter of Opinion "Affluenza" and the Millitant Patient Syndrome. 
  Lanier, B.Q., Tarrant County Physician
  1/1/1986
• "The Fate of Private Practice" 
  Lanier BQ, Nightline Guest (ABC)
  1/1/1985
• A Matter of Opinion "Where Did We Go Wrong?" 
  Lanier, B.Q., Tarrant County Physician
  1/1/1985
• "Get to Know Your Patients Before You Meet Them" 
  Lanier, B.Q., Medical Economics, Pg. 121-122
  1/1/1985
• "Media Polls and HMO's" 
  Lanier, B.Q., Medical Portfolio, Vol. 6, No. 1
  1/1/1985
• "Controversies in Allergy" 
  Lanier BQ, Nightline Guest (ABC)
  1/1/1984
• Join now to see all